Your browser is no longer supported. Please, upgrade your browser.
Pacific Biosciences of California, Inc.
Index- P/E- EPS (ttm)-0.28 Insider Own1.30% Shs Outstand187.22M Perf Week-0.80%
Market Cap6.75B Forward P/E- EPS next Y-0.47 Insider Trans-65.51% Shs Float178.29M Perf Month62.41%
Income-45.60M PEG- EPS next Q0.32 Inst Own94.30% Short Float8.76% Perf Quarter185.87%
Sales79.70M P/S84.75 EPS this Y27.30% Inst Trans-0.47% Short Ratio3.20 Perf Half Y854.59%
Book/sh0.78 P/B47.97 EPS next Y-1040.00% ROA-20.40% Target Price24.25 Perf Year655.96%
Cash/sh1.16 P/C32.40 EPS next 5Y-1.00% ROE-63.80% 52W Range2.20 - 41.65 Perf YTD44.26%
Dividend- P/FCF465.84 EPS past 5Y10.10% ROI-116.60% 52W High-10.16% Beta1.28
Dividend %- Quick Ratio1.70 Sales past 5Y8.40% Gross Margin42.80% 52W Low1600.91% ATR3.35
Employees404 Current Ratio1.80 Sales Q/Q-12.80% Oper. Margin-58.10% RSI (14)66.00 Volatility10.12% 11.55%
OptionableYes Debt/Eq0.00 EPS Q/Q25.40% Profit Margin-57.30% Rel Volume0.72 Prev Close36.31
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout- Avg Volume4.88M Price37.42
Recom2.60 SMA2018.52% SMA5059.74% SMA200255.89% Volume3,501,009 Change3.06%
Nov-03-20Downgrade Piper Sandler Overweight → Neutral $12
Oct-02-20Upgrade JP Morgan Neutral → Overweight $15
Sep-09-20Initiated Morgan Stanley Equal-Weight $7
Jun-02-20Resumed Cantor Fitzgerald Overweight $5
Mar-09-20Resumed Cantor Fitzgerald Overweight $5
Oct-15-19Upgrade Piper Jaffray Neutral → Overweight $8
Apr-02-19Downgrade Stephens Overweight → Equal-Weight $4.50 → $8
Oct-19-18Initiated Cowen Outperform
Nov-03-17Downgrade First Analysis Sec Overweight → Equal-Weight $4
Sep-28-17Downgrade CL King Buy → Neutral
Nov-03-16Reiterated Cantor Fitzgerald Buy $18 → $15
Jun-27-16Initiated CL King Buy
Apr-15-16Initiated First Analysis Sec Overweight $11
Feb-04-16Downgrade Piper Jaffray Overweight → Neutral
Jan-04-16Reiterated Cantor Fitzgerald Buy $11 → $18
Oct-23-15Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Initiated Cantor Fitzgerald Buy
Feb-04-15Reiterated Maxim Group Buy $10 → $11
Sep-26-13Reiterated Maxim Group Buy $4 → $8
Jan-14-13Reiterated Maxim Group Buy $3 → $4
Jan-20-21 11:36AM  
Jan-13-21 12:19PM  
Jan-12-21 06:26PM  
Jan-11-21 07:45AM  
Jan-08-21 03:16PM  
Jan-07-21 09:13AM  
Jan-01-21 01:31AM  
Dec-31-20 05:00AM  
Dec-24-20 11:10AM  
Dec-23-20 07:29PM  
Dec-18-20 04:05PM  
Dec-16-20 08:00AM  
Dec-14-20 08:00AM  
Dec-10-20 10:02AM  
Dec-09-20 12:04PM  
Dec-03-20 12:36PM  
Dec-02-20 11:30AM  
Nov-11-20 12:21AM  
Nov-10-20 04:05PM  
Nov-04-20 08:39AM  
Nov-03-20 06:15AM  
Nov-02-20 06:15PM  
Oct-30-20 12:51PM  
Oct-26-20 12:31PM  
Oct-22-20 08:00AM  
Oct-19-20 12:30PM  
Oct-15-20 08:00AM  
Oct-08-20 11:30AM  
Oct-06-20 07:44PM  
Oct-05-20 08:00AM  
Oct-02-20 03:37PM  
Sep-23-20 08:59AM  
Sep-22-20 07:13AM  
Sep-16-20 11:55AM  
Sep-14-20 09:00AM  
Sep-09-20 09:44AM  
Sep-02-20 11:30AM  
Aug-18-20 08:43AM  
Aug-12-20 12:51PM  
Aug-11-20 11:20PM  
Aug-10-20 01:02PM  
Aug-07-20 08:30AM  
Aug-04-20 08:14AM  
Aug-03-20 06:35PM  
Aug-02-20 11:08AM  
Jul-27-20 12:31PM  
Jul-24-20 12:07PM  
Jun-23-20 01:21PM  
Jun-10-20 08:59AM  
Jun-08-20 04:02PM  
Jun-05-20 11:31AM  
May-17-20 06:01PM  
May-08-20 07:57AM  
May-07-20 11:30AM  
May-06-20 04:03PM  
Apr-30-20 10:30AM  
Apr-29-20 12:34PM  
Apr-27-20 01:09PM  
Apr-24-20 12:30PM  
Apr-21-20 07:22AM  
Apr-20-20 07:00AM  
Apr-08-20 07:30AM  
Mar-18-20 01:52PM  
Mar-07-20 11:31AM  
Mar-05-20 06:00PM  
Feb-25-20 05:40PM  
Feb-11-20 10:22AM  
Feb-08-20 06:53PM  
Feb-07-20 04:03PM  
Feb-06-20 06:25PM  
Jan-30-20 12:31PM  
Jan-27-20 05:21AM  
Jan-21-20 02:16PM  
Jan-03-20 03:34PM  
Jan-02-20 11:58PM  
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry; Invitae Corporation focuses on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. has collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hunkapiller MichaelDirectorJan 22Option Exercise6.14150,857926,262999,262Jan 22 09:49 PM
Hunkapiller MichaelDirectorJan 22Sale36.77150,8575,547,490848,405Jan 22 09:49 PM
Hunkapiller MichaelDirectorJan 21Option Exercise3.31208,711691,4111,106,926Jan 22 09:49 PM
Hunkapiller MichaelDirectorJan 21Sale36.58258,5219,457,071848,405Jan 22 09:49 PM
Hunkapiller MichaelDirectorJan 20Option Exercise2.27215,026488,1091,113,241Jan 22 09:49 PM
Hunkapiller MichaelDirectorJan 20Sale39.19215,0268,426,269898,215Jan 22 09:49 PM
Hunkapiller MichaelDirectorDec 22Option Exercise3.01364,4511,096,9981,262,666Dec 23 06:34 PM
Hunkapiller MichaelDirectorDec 22Sale25.62364,4519,335,716898,215Dec 23 06:34 PM
Hunkapiller MichaelDirectorDec 21Option Exercise2.88335,549965,8771,233,764Dec 23 06:34 PM
Hunkapiller MichaelDirectorDec 21Sale23.00335,5497,718,327898,215Dec 23 06:34 PM
Hunkapiller MichaelDirectorNov 24Sale14.391,49221,4620Nov 25 04:46 PM
Hunkapiller MichaelDirectorNov 23Sale15.03251,8373,785,6141,492Nov 24 04:44 PM
Hunkapiller MichaelDirectorNov 20Sale15.11147,7992,233,538253,329Nov 24 04:44 PM
Hunkapiller MichaelDirectorNov 19Sale15.552,20134,226401,128Nov 20 05:16 PM
Hunkapiller MichaelDirectorNov 18Sale15.7138,381603,004403,329Nov 20 05:16 PM
Hunkapiller MichaelDirectorNov 16Sale15.9042,488675,347441,710Nov 18 04:05 PM
Hunkapiller MichaelDirectorNov 12Sale16.73200,0003,345,800484,198Nov 13 05:17 PM
Hunkapiller MichaelDirectorNov 11Sale16.46250,0004,116,000684,198Nov 13 05:17 PM
Hunkapiller MichaelDirectorNov 11Sale14.25195,6522,788,041898,215Nov 13 05:17 PM
Hunkapiller MichaelDirectorNov 10Sale14.251,304,34818,586,9591,093,867Nov 13 05:17 PM
Hunkapiller MichaelCEO & PresidentAug 25Sale6.44228,6321,472,619934,198Aug 26 05:08 PM
MILLIGAN JOHN FDirectorAug 24Option Exercise3.32110,000365,200110,000Aug 26 07:29 PM
Hunkapiller MichaelCEO & PresidentAug 24Sale6.63259,1641,719,4751,162,830Aug 26 05:08 PM
Hunkapiller MichaelCEO & PresidentAug 21Sale6.57189,8471,246,9151,421,994Aug 24 06:04 PM
Hunkapiller MichaelCEO & PresidentAug 20Sale6.47256,5541,659,8021,611,841Aug 24 06:04 PM
Phillips James MichaelSVP, Research & DevelopmentMar 24Sale3.052,7608,421249,220Mar 24 06:12 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 20Sale4.50166,575749,7541,868,395Feb 24 04:15 PM
Phillips James MichaelSVP, Research & DevelopmentFeb 20Sale4.485,05022,624251,980Feb 24 05:55 PM
BARNES SUSAN KEVP, CFO and PAOFeb 19Sale4.4412,55855,758874,812Feb 25 07:09 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 19Sale4.4976,281342,3492,034,970Feb 20 05:33 PM
Hunkapiller MichaelChairman, CEO & PresidentFeb 18Sale4.49525,9952,363,2962,111,251Feb 20 05:33 PM